Insulet Raises 2026 Growth Outlook and Unveils $1 Billion Buyback as Q3 Revenue Rises 19.2%
Insulet beat its own third-quarter sales forecast, raised its 2026 growth outlook and unveiled a $1 billion share repurchase program, according to its 8-K released Wednesday.
Revenue rose 19.2% to $842.0 million, or 19.6% in constant currency, slightly above the top of its 17.5% to 19.5% guidance range. Net income climbed to $141.1 million, or $2.03 per diluted share, from $87.6 million, or $1.24, a year earlier. Adjusted EPS rose 59.9% to $1.99.
International Omnipod surges
Total Omnipod revenue grew 19.7% to $836.6 million. U.S. Omnipod sales increased 14.7% to $570.4 million, while international Omnipod sales jumped 31.7% to $266.2 million.
Operating margin widened 590 basis points to 22.5% of revenue, and adjusted operating margin rose 490 basis points to 22.0%.
The tubeless insulin pump maker said it completed its U.S. sales force expansion and is executing a Type 2 diabetes action plan focused on onboarding, sampling and sales compensation tied to new customer starts and retention. It also completed enrollment in its STRIVE2 trial supporting Omnipod 6 and its EVOLVE pivotal study of fully closed-loop insulin delivery for adults with Type 2 diabetes.
Buyback and guidance
The board approved a $1 billion share repurchase program, and the company expects to put an estimated $400 million toward repurchases in the fourth quarter, the company said.
Insulet now expects 2026 total revenue growth of 21% to 22% in constant currency, up from 20% to 22%. Guidance for international Omnipod growth rises to 32% to 33% from 30% to 32%, while U.S. Omnipod growth narrows to 17.5% to 18.5%. The company also raised its expected adjusted operating margin expansion to 150 basis points from 100 basis points, and still expects adjusted EPS growth above 30%.
By the numbers
- Q3 revenue: $842.0 million, up 19.2%
- Diluted EPS: $2.03 vs. $1.24
- Adjusted EPS: $1.99, up 59.9%
- New buyback: $1 billion
- 2026 revenue growth guidance: 21% to 22%
Sources
- Insulet Form 8-K with third-quarter 2026 earnings release, filed Nov. 4, 2026 (accession 0001145197-26-000190)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.